Senseonics (NYSE:SENS) is a medical technology company specializing in the development and commercialization of long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s flagship product, the Eversense™ CGM System, features a small, implantable sensor designed to be worn under the skin for up to 90 days (and in some markets up to 180 days), a removable smart transmitter that sits on top of the skin, and a mobile application that provides real-time glucose data, trend information and customizable alerts. This unique combination of sensor longevity and real-time monitoring aims to improve patient adherence and quality of life by reducing the frequency of sensor replacements compared to traditional CGM devices.
Senseonics targets both the consumer and professional healthcare markets, offering its CGM technology to endocrinologists, diabetes educators and primary care physicians. The Eversense system is indicated for adults with type 1 and type 2 diabetes and can be integrated into the broader diabetes management ecosystem through Bluetooth connectivity. The company conducts ongoing clinical research to explore expanded indications, such as use in pediatric populations and in individuals with gestational diabetes, as well as enhancements to sensor accuracy and wearability.
Commercially, Senseonics has established a presence in the United States, where it secured FDA approval in 2018, and in Europe, where it began distributing the Eversense system following CE mark clearance. In addition to direct sales, the company has entered into strategic partnerships and distribution agreements to extend its reach, including collaborations with major pharmaceutical and medtech organizations. These alliances not only bolster market penetration but also support reimbursement efforts in various countries, facilitating broader patient access.
Founded in 2006 and headquartered in Germantown, Maryland, Senseonics was co-founded by medical device veterans Christian Cotichini, Perry S. Dorsey and Dr. A.J. Vater. Under the leadership of President and Chief Executive Officer Timothy Diamond, the company continues to invest in research and development aimed at enhancing sensor performance, simplifying insertion and removal procedures, and integrating advanced data analytics. By focusing on innovative CGM solutions, Senseonics strives to play a pivotal role in transforming diabetes management and improving outcomes for patients worldwide.
